The Next Generation of Drug Resistant Tuberculosis Drug Design

Overview

Journal Future Med Chem

Date 2025 Jan 15

PMID 39814693

Authors

Vinayak Singh

Affiliations

Soon will be listed here.

References

Kling A, Lukat P, Almeida D, Bauer A, Fontaine E, Sordello S . Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins. Science. 2015; 348(6239):1106-12. DOI: 10.1126/science.aaa4690. View

Cebi E, Lee J, Subramani V, Bak N, Oh C, Kim K . Cryo-electron microscopy-based drug design. Front Mol Biosci. 2024; 11:1342179. PMC: 10945328. DOI: 10.3389/fmolb.2024.1342179. View

Akalu T, Clements A, Wolde H, Alene K . Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis. Sci Rep. 2023; 13(1):22361. PMC: 10724290. DOI: 10.1038/s41598-023-47094-9. View

van der Klugt T, van den Biggelaar R, Saris A . Host and bacterial lipid metabolism during tuberculosis infections: possibilities to synergise host- and bacteria-directed therapies. Crit Rev Microbiol. 2024; :1-21. DOI: 10.1080/1040841X.2024.2370979. View

Gries R, Chhen J, van Gumpel E, Theobald S, Sonnenkalb L, Utpatel C . Discovery of dual-active ethionamide boosters inhibiting the Mycobacterium tuberculosis ESX-1 secretion system. Cell Chem Biol. 2024; 31(4):699-711.e6. DOI: 10.1016/j.chembiol.2023.12.007. View

Koltringer F, Annerstedt K, Boccia D, Carter D, Rudgard W . The social determinants of national tuberculosis incidence rates in 116 countries: a longitudinal ecological study between 2005-2015. BMC Public Health. 2023; 23(1):337. PMC: 9930041. DOI: 10.1186/s12889-023-15213-w. View

Nikiforov P, Blaszczyk M, Surade S, Boshoff H, Sajid A, Delorme V . Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. ACS Chem Biol. 2017; 12(5):1390-1396. PMC: 5474694. DOI: 10.1021/acschembio.7b00091. View

Liang S, Ma J, Wang G, Shao J, Li J, Deng H . The Application of Artificial Intelligence in the Diagnosis and Drug Resistance Prediction of Pulmonary Tuberculosis. Front Med (Lausanne). 2022; 9:935080. PMC: 9366014. DOI: 10.3389/fmed.2022.935080. View

Singh V, Chibale K . Strategies to Combat Multi-Drug Resistance in Tuberculosis. Acc Chem Res. 2021; 54(10):2361-2376. PMC: 8154215. DOI: 10.1021/acs.accounts.0c00878. View

10.

Alffenaar J, Akkerman O, Kim H, Tiberi S, Migliori G . Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. Int J Infect Dis. 2020; 92S:S5-S9. DOI: 10.1016/j.ijid.2020.01.041. View

11.

Dehbanipour R, Ghalavand Z . Anti-virulence therapeutic strategies against bacterial infections: recent advances. Germs. 2022; 12(2):262-275. PMC: 9719373. DOI: 10.18683/germs.2022.1328. View

12.

Qin Z, Ahmed S, Sarker M, Paul K, Adel A, Naheyan T . Tuberculosis detection from chest x-rays for triaging in a high tuberculosis-burden setting: an evaluation of five artificial intelligence algorithms. Lancet Digit Health. 2021; 3(9):e543-e554. DOI: 10.1016/S2589-7500(21)00116-3. View

13.

Flipo M, Frita R, Bourotte M, Martinez-Martinez M, Boesche M, Boyle G . The small-molecule SMARt751 reverses resistance to ethionamide in acute and chronic mouse models of tuberculosis. Sci Transl Med. 2022; 14(643):eaaz6280. DOI: 10.1126/scitranslmed.aaz6280. View

14.

McClean M, Panciu T, Lange C, Duarte R, Theis F . Artificial intelligence in tuberculosis: a new ally in disease control. Breathe (Sheff). 2024; 20(3):240056. PMC: 11629172. DOI: 10.1183/20734735.0056-2024. View

15.

Bekele A, Gebreselassie N, Ashenafi S, Kassa E, Aseffa G, Amogne W . Daily adjunctive therapy with vitamin D and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia. J Intern Med. 2018; 284(3):292-306. PMC: 6202271. DOI: 10.1111/joim.12767. View

16.

Preiss L, Langer J, Yildiz O, Eckhardt-Strelau L, Guillemont J, Koul A . Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv. 2015; 1(4):e1500106. PMC: 4640650. DOI: 10.1126/sciadv.1500106. View